World Immunization Week from April 24-30 gives us the opportunity to celebrate one of the greatest achievements of modern medicine. Safe and effective vaccines that protect individuals against diphtheria, hepatitis B, measles, mumps, pertussis, rubella, human papilloma virus, and polio have drastically limited the incidence of these serious, sometimes life-threatening diseases in many parts of the world. Immunizations against infectious diseases that cause severe illness, disability and death save from 2 million to 3 million lives annually and prevent the spread of infections that can be resistant to treatments. This week also is a time to reflect on the public health benefits of immunization, with high rates of vaccination across communities providing indirect protection through herd immunity for populations including very young children, pregnant women, and people with weakened immune systems who cannot be vaccinated. Across the U.S. and globally, universal access to vaccines is critical to their optimal effectiveness. Gaps in coverage anywhere can pose threats of re-emerging diseases, particularly among the most vulnerable populations everywhere.

This year, World Immunization Week brings reminders that globally, vaccine coverage remains far from adequate. Currently, 19.5 million children lack access to basic vaccines against diphtheria-tetanus-pertussis and remain vulnerable to these preventable yet potentially deadly infectious diseases. And, while measles vaccinations have prevented more than 20 million deaths since the turn of this century, making that vaccine one of the most cost-effective investments in public health, measles remains one of the leading causes of death worldwide among children under five.

While the United States has made significant progress toward eliminating vaccine-preventable diseases among children, coverage continues to lag for adolescents and adults.  Every year, more than 50,000 adults in the U.S. die from vaccine-preventable illnesses. Annually, the U.S. spends $26.5 billion treating four vaccine-preventable illnesses in adults—influenza, shingles, pertussis and pneumococcal disease. In addition, ill-informed policies allowing personal belief-based exemptions for childhood immunization requirements have contributed to depressed vaccination rates in some communities, followed by predictable measles outbreaks. Travelers continue to bring measles into the U.S. where, upon reaching communities where significant numbers of people remain unvaccinated, the disease spreads.

The Infectious Diseases Society of America, the Pediatric Infectious Diseases Society and the Society for Healthcare Epidemiology of America support universal immunization of children, adolescents, and adults, based on current scientific evidence and according to the recommendations and standards established by the National Vaccine Advisory Committee, the U.S. Centers for Disease Control and Prevention, and the CDC’s Advisory Committee on Immunization Practices. For CDC’s advisory committee to recommend a vaccine, the vaccine must demonstrate significant patient benefit and very low risk. To secure approval from the Food and Drug Administration, vaccines are often required to present more rigorous safety and efficacy data than drugs or devices. We strongly encourage states to enact and enforce laws requiring all children without medical contraindications to be fully immunized as a requirement for school or daycare. We support robust funding for CDC immunization programs that help ensure access to immunizations and respond to outbreaks of vaccine-preventable diseases. We also support improved Medicare coverage of vaccines and increased investment in vaccine registries or immunization information systems across the lifespan to increase uptake of recommended vaccines, including for pneumococcal disease, shingles and influenza for at-risk adults, including elderly individuals. We recognize the importance of policies requiring vaccination among healthcare workers to protect their health and that of their vulnerable patients.

We call on policymakers to continue investments in vaccine research and development needed to bring new and improved vaccines, including a universal influenza vaccine, to market, and to remain invested in ensuring the availability of these critical public health tools.


IDSA: Jennifer Morales This email address is being protected from spambots. You need JavaScript enabled to view it.

PCI Public Relations (312) 558-1770 This email address is being protected from spambots. You need JavaScript enabled to view it.

PIDS: Terri Christene Phillips, MSA This email address is being protected from spambots. You need JavaScript enabled to view it.

SHEA: Kristy Weinshel This email address is being protected from spambots. You need JavaScript enabled to view it.

Paul Auwaerter, MD, MBA, President IDSA

Paul Spearman, MD, FPIDS, President PIDS

Keith Kaye, MD, MPH, FSHEA


IDSA, SHEA and PIDS Announce Inaugural LEAP Fellowship Awardees 

IDSA, SHEA and PIDS are pleased to announce the first awardees of the Leadership in Epidemiology, Antimicrobial Stewardship, and Public health (LEAP) Fellowship. Currently in its inaugural year, the LEAP Fellowship is a $100,000 training award competitively granted to four promising young infectious diseases physicians. Funded by the Centers for Disease Control and Prevention, this fellowship aims to foster the next generation of Infectious Diseases leaders in public health, hospital epidemiology and antimicrobial stewardship, giving them the hands-on experience they’ll need to lead and collaborate across these disciplines of healthcare.


  • Milner Staub, MD, Vanderbilt University
    Leap Fellowship Project: An Assessment of Outpatient Antimicrobial Prescription Across Tennessee Based on Practice Location, Specialty and Provider
  • Dana Pepe, MD, Yale School of Medicine
    Leap Fellowship Project: Expanding Utilization of Targeted Assessment for Prevention (TAP) Strategy in Connecticut
  • Gabriella Andujar Vazquez, MD, Tufts Medical Center
    LEAP Fellowship Project: Enhanced Support for Long Term Care Facilities Participating in a Massachusetts Department of Public Health Antimicrobial Stewardship Initiative
  • Jennifer Blumenthal, MD, Boston Children’s Hospital
    LEAP Fellowship Project: Assessing and Optimizing the Utility of the Massachusetts Statewide Antibiogram

The LEAP Fellowship will commence July 1, 2018 and last one year. The Fellowship is for early career infectious diseases physicians - those in their second or third year of fellowship or up to two years post fellowship.

Societal Leadership Weighs In:

IDSA : “I am proud that we have partnered with SHEA and PIDS along with the CDC who is sponsoring LEAP so that infectious disease fellows or early career clinical ID physicians may gain experience and tools to foster collaboration between academic institutions and public health departments. With antimicrobial resistance a more pressing concern then ever, we wish the awardees success during their fellowship and look to their future for inspired leadership in stewardship, epidemiology and public health.” – Paul Auwaerter, MBA, MD, FIDSA, President of IDSA

SHEA : “The ability to effectively share knowledge and experience among professionals in public health, infection prevention and antibiotic stewardship and to form fruitful collaborative partnerships is critical in improving patient care and reducing antimicrobial resistance. By offering research support and professional opportunities, the Leadership in Epidemiology, Antimicrobial Stewardship, and Public health (LEAP) Fellowship will help to train future leaders in healthcare epidemiology. We are extremely excited to join IDSA and PIDS in awarding these inaugural LEAP Fellowships,” – Keith Kaye, MD, MPH, president of SHEA

PIDS : “The LEAP fellowships recognize outstanding young ID physicians who are poised to become leaders in public health, hospital epidemiology and antimicrobial stewardship. The Pediatric Infectious Diseases Society (PIDS) is excited to be a part of the inaugural LEAP fellowship awards, and would like to congratulate the four awardees. This is an area of great importance to the future of ID and to the health of our nation.”– Paul W. Spearman, MD, FPIDS

For more information on the LEAP Fellowship, please contact, Michele Wagner, MPH, LEAP Fellowship Project Manager at This email address is being protected from spambots. You need JavaScript enabled to view it.. For more information from CDC, please contact Karima Hunter, Project Manager at This email address is being protected from spambots. You need JavaScript enabled to view it..

On behalf of the National Foundation for Infectious Diseases (NFID), the latest NFID Call to Action: Improving Healthcare Personnel Immunization Rates, addressing how to best optimize practices that will lead to improved immunization rates among healthcare personnel. The recommendations in this Call to Action are based upon the discussions at a November 2017 Summit convened by NFID which included representatives from professional healthcare organizations active in infection prevention and control, occupational health, and immunization.

It is well recognized that vaccination is among the most cost-effective clinical preventive services currently available in the US. In looking specifically at healthcare personnel (HCP), vaccination efforts have been shown to reduce or eliminate the spread of disease to prevent illness among patients served and to reduce the need for medical visits, missed days of work, productivity loss, and medical errors. Those benefits are identified throughout the 2011 US Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) recommendations for HCP immunization.
How PIDS Members Can Get Involved

Upcoming Complimentary NFID Webinar 

Thursday, April 5, 2018 at 12:00 PM ET

Improving Healthcare Personnel (HCP) Immunization Rates

Join NFID Medical Director William Schaffner, MD; Ruth M. Carrico, PhD, NP, CIC, University of Louisville; and Patricia A. Stinchfield, RN, MS, CPNP, CIC, Children’s Minnesota, for engaging presentations on specific strategies and best practices to increase HCP immunization in various healthcare settings. 

At the conclusion of this activity, participants will be able to:

• Review the current US recommendations for healthcare personnel and immunization rates

• Understand issues, challenges, and opportunities that may impact HCP immunization acceptance

• Discuss best practices and practical strategies to increase HCP immunization rates in various healthcare settings

There is no fee to participate in this activity but pre-registration is required:

Nearly a third of all antibiotics prescribed for hospitalized children globally were intended to prevent potential infections rather than to treat disease, according to the results of a worldwide survey published in the Journal of the Pediatric Infectious Diseases Society. A large proportion of these preventive, or prophylactic, prescriptions also were for broad-spectrum antibiotics or combinations of antibiotics, or were for prolonged periods, which can hasten the development of antibiotic-resistant bacteria and drug-resistant infections.

“This pattern and high rate of prophylactic prescribing indicates a clear overuse of antibiotics,” said study author Markus Hufnagel, DTM&H, of the University of Freiburg in Germany. “Hopefully, our study results will help to raise awareness among health professionals about appropriate prescribing of antibiotics in children,” Dr. Hufnagel said.

The study provides a snapshot of antibiotic prescriptions for 6,818 children who were inpatients at 226 pediatric hospitals in 41 countries, including four hospitals in the United States, during one day in 2012. There were 11,899 total prescriptions for antibiotics, and 28.6 percent of these were for prophylactic use, researchers found. Among hospitalized children who received at least one antibiotic prescription, 32.9 percent (2,242 children) were prescribed an antibiotic to prevent a potential infection rather than to treat a current one.

Of the antibiotics prescribed for prophylactic use, 26.6 percent were to prevent potential infections associated with an upcoming surgery, and the vast majority of these antibiotics were given for more than one day. The remaining 73.4 percent of the prophylactic prescriptions were intended to potentially prevent other types of infections. Approximately half (51.8 percent) of all preventive antibiotic prescriptions were for broad-spectrum antibiotics. In 36.7 percent of cases, two or more systemic antibiotics were prescribed at the same time.

These patterns contradict current recommendations for appropriate prophylactic antibiotic use. Guidelines often call for using narrow-spectrum antibiotics for shorter periods, in an effort to limit the development of antibiotic resistance. The study findings suggest clear targets for improving antibiotic prescribing in pediatric patients, according to the authors. These include reducing prolonged, preventive antibiotic use before surgery, limiting the use of broad-spectrum and combinations of antibiotics, and reducing antibiotic use, overall, for prophylactic rather than therapeutic use.

Additional education for clinicians and improved implementation of current guidelines for antibiotic use to prevent surgical infections are needed, Dr. Hufnagel said. More in-depth guidelines that address the use of prophylactic antibiotics for a broader range of medical conditions than current guidelines do are also needed, as well as efforts to communicate these guidelines to health care providers and to analyze how the recommendations are used.

Fast Facts

  • A survey of hospitals in 41 countries suggests antibiotics are often inappropriately and excessively prescribed for hospitalized children worldwide.
  • Nearly a third of all antibiotics prescribed for these children were for preventive, or prophylactic, use, rather than to treat disease, the survey found.
  • The use of broad-spectrum antibiotics and combinations of antibiotics was also high, raising concerns about increased risk for the development of antibiotic resistance and drug-resistant infections.

Editor’s Note: The study was funded by the European Commission Directorate General for Health and Consumers and the Paediatric European Network for Treatment of AIDS. For an embargoed copy, please contact Terri Christene Phillips, MSA (This email address is being protected from spambots. You need JavaScript enabled to view it., 703-299-9865).


Published quarterly, the Journal of the Pediatric Infectious Diseases Society represents the spectrum of peer-reviewed, scientific and clinical information on perinatal, childhood, and adolescent infectious diseases. The journal is a publication of the Pediatric Infectious Diseases Society (PIDS), the world's largest professional organization of experts in the care and prevention of infectious diseases in children.

PIDS membership encompasses leaders across the global scientific and public health spectrum, including clinical care, advocacy, academics, government, and the pharmaceutical industry. From fellowship training to continuing medical education, research, regulatory issues and guideline development, PIDS members are the core professionals advocating for the improved health of children with infectious diseases both nationally and around the world, participating in critical public health and medical professional advisory committees that determine the treatment and prevention of infectious diseases, immunization practices in children, and the education of pediatricians. For more information, visit

In August, 2008, UpToDate®, in conjunction with Texas Children’s Hospital, established a series of pediatric subscription awards in honor of Dr Ralph David Feigin, who had been Editor-In-Chief of the Pediatrics Section of UpToDate since its inception in 1999.  The award program grants up to six, three-year subscriptions to UpToDate®  to physicians, other health care providers, or health care facilities that provide care to underserved or low-income children and who could not otherwise afford the subscription.  The deadline for applications is May 31. Awardees will be announced in June, and the subscriptions will start in July, 2018. 


Applicants must meet all four (A, B, C, and D) of the following qualifications.

  1. Practice or teach in low-income or medically underserved areas.
    A low-income or medically underserved area is defined as meeting any one of the following:
    1. a rural area more than 50 miles from the nearest city with a population of 400,000 or more and more than 50 miles from a medical school
    2. a practice in which 50% or more of the patients are uninsured, are insured by a governmental program or are identified as minorities
    3. a community or area designated by a governmental agency or governmental representative as medically underserved or qualifies as a health professional shortage area
    4. a low income country as designated by the WHO
  2. Deliver health care to children or health education to children and their families
  3. Do not currently have access to UpToDate® and are unable to afford the initial one-year subscription of approximately $500 and the approximately $400 yearly renewal fee.
  4. Have access to a computer with internet capability.

Application Process

Applicants should complete the application below electronically.  Cells may be expanded as needed. 

Completed applications (as a word document) should be returned to Martin I Lorin, MD (This email address is being protected from spambots. You need JavaScript enabled to view it.) by May 31, 2018. Click here to download an application.


Parental pressure is frequently cited by pediatric practitioners as a primary reason for antibiotic overuse and inappropriate prescribing.1,2 However, a recent study published by Szymczak and colleagues in the Journal of the Pediatric Infectious Diseases Society brings these widely held beliefs into question. Their findings suggest pediatricians may overestimate the parental desire for antibiotics and that the “culture of expectation” is not as pervasive as some may think. This study, performed at four relatively diverse, hospital-affiliated practices in the Philadelphia area, explored parental perceptions about antibiotics and antimicrobial resistance. Parents accompanying their child to a sick visit for an acute respiratory tract infection (ARTI) were invited to participate in a semistructured interview prior to seeing the child’s physician. A total of 109 parents participated, with wide representation in parental age, race, and socioeconomic status.

Many important themes were revealed during this qualitative analysis. First, most parents were not necessarily expecting antibiotics at their visit. In fact, many parents were hoping their child would not need any antibiotics. Instead, they expected a clear diagnosis, reassurance that there wasn’t something more serious going on, and advice on how to mitigate symptoms. This is in line with previous studies in which a minority of parents expressed a preference for antibiotics or decreased satisfaction when antibiotics were not prescribed.1,3 Second, these parents were not planning to specifically request an antibiotic and conveyed high levels of trust in their child’s pediatrician. This is in contrast to previous studies in which clinicians believed a prescription for antibiotics would actually increase patient satisfaction and reinforce the doctor-patient relationship.1 Finally, although most parents had some knowledge of antibiotic resistance, the level of understanding varied and they were not concerned about antibiotic resistance in themselves or their child. Additionally, many parents recognized overuse of antibiotics as an important issue, but felt other parents were primarily responsible. Interestingly, this mirrors the beliefs of many pediatricians who perceive other providers as contributing to inappropriate prescribing more than themselves.

It’s important to recognize some of the potential limitations of the study. It was performed in a single area in the United States, which may limit generalizability. Additionally, as the authors point out, there may have been a selection bias since these parents generally had to arrive on time or early to their appointment in order to be included. There may also have been some social-desirability bias at play, with parents giving answers they thought would be more acceptable.

This study is a good wake-up call that when it comes to antibiotic overuse, though parental pressure and expectations are contributing factors they may not play as large of a role as some think. Instead, we all share the blame and must also share the responsibility for finding solutions. As the authors suggest, promoting ownership of the problem, with both parents and physicians, will be an important step in future efforts. Parents are key stakeholders in antimicrobial stewardship and need to be engaged in the discussion in order to make further progress, especially in the outpatient setting.


  1. Lucas PJ, Cabral C, Hay AD, Horwood J. A systematic review of parent and clinician views and perceptions that influence prescribing decisions in relation to acute childhood infections in primary care. Scandinavian journal of primary health care. Mar 2015;33(1):11-20.
  2. Szymczak JE, Feemster KA, Zaoutis TE, Gerber JS. Pediatrician perceptions of an outpatient antimicrobial stewardship intervention. Infection control and hospital epidemiology. Oct 2014;35 Suppl 3:S69-78.
  3. Vaz LE, Kleinman KP, Lakoma MD, et al. Prevalence of Parental Misconceptions About Antibiotic Use. Pediatrics. Aug 2015;136(2):221-231.
  4. Julia E Szymczak, Sarah B Klieger, Matthew Miller, Alexander G Fiks, Jeffrey S Gerber; What Parents Think About the Risks and Benefits of Antibiotics for Their Child’s Acute Respiratory Tract Infection, Journal of the Pediatric Infectious Diseases Society. 2017 Sept 14

Statement of the Infectious Diseases Society of America, HIV Medicine Association and the Pediatric Infectious Diseases Society

ARLINGTON, VA. (December 18, 2017) – We are deeply concerned about reports that budget documents submitted to Congress from the Centers for Disease Control and Prevention (CDC) may be censored for certain terms that include “science-“ and “evidence-based,” “transgender” “diversity” “entitlement” “vulnerable” and “fetus.” We find this unacceptable and disturbing. We strongly urge elected officials to prohibit any form of censorship that interferes with accurate communications by CDC, other Department of Health and Human Services agencies and other federal agencies.

As physicians and scientists, our work in patient care and research is based on findings gathered through quality scientific methods that seek to minimize bias. By starting on an objective and a neutral foundation, trust may be established so that patients and therefore the nation’s public health may be protected and advanced.

Censorship driven by political means vested in ideology rather than science threatens to disrupt a prime goal of government: protecting public safety. No different than protecting our shores from military invasion or policing internal strife in our communities, loss of clear and impartial research and recommendations compromises the CDC and the work of other federal agencies. For example, CDC will be deprived to fully conduct safeguarding work essential against new and emerging infections as well as understanding health concerns in all sectors of our society. The impact of censoring science and scientists at the federal level will be serious and far-reaching, not only for the country’s health, but also trust in government itself.

Suppression of language in budget documents suggests further intent--thwarting a federal agency from requesting funding for public health initiatives based on sound science, yet controversial in the political arena. Transgender Americans, for example, have multiple health challenges that impact not only their personal health but also have potential direct impact on a wider community, ranging from sexually-transmitted infections to higher risk for mental health issues and cancer that also increase costs to the health system. While there is, unfortunately, ideological controversy surrounding the rights of transgender persons, facts regarding their health should not be expunged.

Likewise, “fetus” is a scientific word necessary to describe efforts to investigate the health of pregnant women and infants, whether to prevent birth defects caused by the emerging Zika virus infection or to curtail the opioid epidemic’s devastating impact on infant and child health and mortality. While politicians may debate funding for initiatives based on ideology, no elected official should tolerate censoring health science communications, including science-based budget requests from its federal agencies.

We also are concerned that restricting budget documents may lead to additional problems driven by potential censorship. When ideology, fear, and ignorance dominate discourse in the public health arena, consequences are deadly. More than three decades ago when HIV first appeared in the U.S., the federal government’s unwillingness to acknowledge the epidemic and to allocate resources allowed the HIV epidemic to expand further and faster. These early, federal inactions were not based on science but rather grounded in ideology and politics. Timely intervention could have saved many thousands of lives.

If as reported, the current administration recommended the substitution of “science in consideration with community norms and standards” to replace “evidence-based” and “science-based” this is dangerous and misleading. This substitution, perhaps unintentionally, will stifle innovation and lead to dangerous consequences. If community sentiment results in higher rates of unimmunized schoolchildren, there will be more outbreaks such as the recent measles epidemics in California and Ohio all attributed to children not receiving the vaccine. Conversely, our national responses to Ebola virus and more recently Zika virus demonstrate how outbreaks can be quickly and effectively controlled using evidence-based techniques. While community concerns should be acknowledged, they should not override compelling scientific findings.

The CDC is our premier public health agency and serves as a leader worldwide in tackling serious challenges including antibiotic resistance, the opioid epidemic, HIV, sexually transmitted infections, tuberculosis, viral hepatitis, and emerging threats such as Ebola and Zika. The CDC must be fully engaged to prepare for the next infectious threat to our country. The agency’s critical work saves lives from newborns to seniors because it is, and must be, informed by worthy science. If the agency and its scientists and public health officials and those from other federal agencies are banned from, or encouraged to avoid, using scientifically accurate terms, their work will be greatly compromised, and the public will be gravely disserved.

# # #

About IDSA

The Infectious Diseases Society of America (IDSA), based in Arlington, Va., is a professional society representing more than 11,000 physicians and scientists who specialize in infectious diseases. IDSA’s purpose is to improve the health of individuals, communities, and society by promoting excellence in patient care, education, research, public health, and prevention relating to infectious diseases. For more information, visit Follow IDSA on Facebook and Twitter.


HIVMA is an organization of nearly 5,000 clinicians and researchers whose professional focus is HIV medicine. HIVMA’s mission is to promote quality in HIV care by advocating policies and supporting programs that ensure a comprehensive and humane response to the AIDS pandemic informed by science and social justice. Nested within the Infectious Diseases Society of America, HIVMA's work includes creating clinical and educational tools and resources; supporting clinical training and research opportunities to build HIV workforce capacity; and promoting policies and programs to improve access to HIV prevention and care.

About PIDS

PIDS is the world's largest organization of professionals dedicated to the treatment, control and eradication of infectious diseases affecting children. Membership is comprised of physicians, doctoral- level scientists and others who have trained or are in training in infectious diseases or its related disciplines, and who are identified with the discipline of pediatric infectious diseases or related disciplines through clinical practice, research, teaching and/or administration activities.

Welcome to our educational modules for Pediatric Transplant Infectious Diseases, developed in collaboration with the Pediatric Infectious Diseases Society and the American Society for Transplantation. We recognized that this specialized area of pediatric ID care is a rapidly changing and growing practice area, with few resources to help us in management. The modules are intended to help pediatric ID fellows and faculty in their management of these patients.

Pediatric Transplant Infectious Diseases Educational Modules (Login required)

The recent issue of JPIDS featured a notable study by Hysmith et al which makes us rethink our approach of differentiating between “harmless” pharyngeal carriage of group A streptococcus (GAS) versus actual infection. The study longitudinally assesses the human immune response to natural infection with GAS [1], and as Shulman et al point out in their accompanying editorial, the findings challenge our current understanding of pharyngeal colonization versus infection with GAS, and the immunologic responses associated with colonization versus infection [2].

Taking a subset of subjects from a larger study conducted at multiple U.S. academic centers, they looked at 41 children who experienced 51 new pharyngeal acquisitions of GAS during a two year study period [3, 4]. They defined a new acquisition as a throat culture that was positive for an emm type of GAS that had not been isolated previously, with a subsequent immune response to 1 or more of the antigens studied. The 31 GAS antigens studied included 18 M peptides and 13 other shared GAS antigens, chosen based on previous studies that indicated their immunogenicity and potential as vaccine candidates, and included streptolysin O (SLO) and deoxyribonuclease B (DNaseB). They evaluated serial throat cultures and 195 serum samples obtained on enrollment and at scheduled intervals throughout the study and when subjects had signs or symptoms of pharyngitis. Salient results included the following:

  • 32 (63%) of the 51 episodes produced an antibody response to the homologous M peptide (i.e. the M type of the strain cultured from the throat produced an antibody response to the same M type in the serum).
  • No subjects had a new acquisition of an M type against which they had preexisting antibodies to the homologous M type.
  • 65% of subjects with new acquisition of GAS were asymptomatic, but mounted immune responses to 1 or more (average 3.7) antigens.
  • 67% of new GAS acquisitions elicited an immune response to SLO and/or DNaseB.
  • 8 (20%) subjects had persistently positive throat culture results (>12 weeks) despite immune responses to homologous M peptides and/or shared antigens.
  • No shared antigen consistently evoked an immune response after a new GAS acquisition.

Given their observation that 65% of subjects had asymptomatic GAS acquisition, yet mounted an immune response to the acquisition, the majority of infections would not be detected based on symptoms alone, and therefore could cause missed opportunities for antimicrobial treatment and prevention of rheumatic fever and rheumatic heart disease. In addition, not all patients actually mount a response to SLO and/or DNaseB, the most commonly used commercially available GAS antibody tests used in the evaluation of patients with suspected acute rheumatic fever or post-streptococcal glomerulonephritis. This means that a negative ASO and/or DNaseB test does not necessarily prove a patient did not have a prior GAS infection and suggests a need to expand the panel of tests available for the clinical evaluation of patients for post-streptococcal nonsuppurative complications.

Shulman et al point out that the study gives us some answers, but also raises important questions that “challenge long standing dogma” for us in how to best prevent the sequelae of GAS [2]. They highlight the bottom line that “(1) anti-M protein protects against a new acquisition of GAS in a type-specific fashion; (2) our previous concepts about a significant GAS acquisition requiring demonstrable increases in antibodies to non-M protein antigens and/or to M protein antigens may not be true and (3) whether or not a new GAS acquisition is significant—risk for post-streptococcal sequelae, whether or not a new GAS acquisition is significant appears to be unrelated to symptomatic or symptomatic acquisition status, whether or not antibiotics were administered promptly, and whether there was or was not a clear immune response to classical streptococcal antigens.”

So perhaps to answer “Where do we go from here?” the first step is for clinicians to be aware of these important findings in their management of patients and assessment of post-streptococcal sequelae. It remains to be seen how these findings and the work that comes after will impact the availability of other GAS serologic tests, changes in GAS treatment guidelines, and the development of a GAS vaccine.


  1. Hysmith ND, Kaplan E, Cleary PP, et al. Prospective Longitudinal Analysis of Immune Responses in Pediatric Subjects After Pharyngeal Acquisition of Group A Streptococci. Journal of the Pediatric Infectious Diseases Society 2017;6(2):187–96.
  2. Shulman ST, Tanz RR. Strep: Where Do We Go From Here? Journal of the Pediatric Infectious Diseases Society 2017;6 (2):197–8.
  3. Kurlan R, Johnson D, Kaplan EL. Streptococcal infection and exacerbations of childhood tics and obsessive-compulsive symptoms: a prospective blinded cohort study. Pediatrics 2008; 121:1188–97.
  4. Leckman JF, King RA, Gilbert DL, et al. Streptococcal upper respiratory tract infections and exacerbations of tic and obsessive-compulsive symptoms: a prospective longitudinal study. J Am Acad Child Adolesc Psychiatry 2011; 50:108–18 e3.

After a brief warm welcome from our host Jason Newland, MD, from Washington University in St. Louis, the conference began with the much requested “ASP Basic Workshop”. Sarah Parker, MD, Children’s Hospital Colorado, explained how to use the antimicrobial stewardship “elevator speech” to develop a business plan and described successful strategies to pitch antimicrobial stewardship to the C-suite. Her pharmacy counterpart from Children’s Hospital Colorado, Amanda Hurst, PharmD, then outlined the ASP pharmacists’ role(s) as a jack of all trades, explained to new ASP pharmacists basic tools and understanding of what this role can accomplish, while illustrated to experienced ASP pharmacists concrete examples of the “handshake stewardship” model that has been so successful at her institution. Pranita Tamma, MD, from Johns Hopkins led a case-based discussion reviewing resistance mechanisms among gram negative bacteria and highlighted the latest literature supporting treatment options for patients with multidrug resistant gram negative infections including new antibiotics on the horizon such as plazomicin, fosfomycin, and aztretonam-avibactam. The addition of breakout sessions this year allowed an opportunity for physicians, pharmacists, and trainees to bring forth questions to their individual breakout groups for free discussion. These unstructured discussions facilitated the opportunity to informally benchmark and gauge how our peers approach common antimicrobial stewardship challenges and provided volumes of useful information.

In the afternoon, the “ASP Academic Conference” started off with duo David Hyun, MD, and Holly Maples, PharmD, returned for the popular annual “Literature Support for Antimicrobial Stewardship", and reviewed their selected “top ten” papers of the year relevant to pediatric antimicrobial stewardship. Dr. Hurst returned to the podium to discuss how to maximize pharmacokinetics and pharmacodynamics (including a compare/contrast of oral third generation cephalosporins) for the treatment of infections.

The PIDS Antimicrobial Stewardship Fellowship Award supports the development of future researchers in pediatric antimicrobial stewardship by providing mentorship to complete a scholarly research project during fellowship or residency. The project(s) awarded should be completed in one year, and the award provides travel funds to present their work at this annual conference.

The 2016 awardees delivered outstanding presentations of their work:

  • Kathleen Chiotos, MD, Children’s Hospital of Philadelphia “Empiric Antibiotic Use in Pediatrics: A Potential Opportunity for Antibiotic Stewardship”
  • Dustin Flannery, MD, Children’s Hospital of Philadelphia “Temporal Trends in Antibiotic Use for Risk of Early-Onset Sepsis Among Very Premature Infants Across the United States” and
  • Anna Sick-Samuels, MD, Johns Hopkins University “Characterizing Risk Factors for Multidrug-Resistant Gram-Negative Bloodstream Infections in Children”.

Concluding the first day of the conference, panel members Drs. Parker, Hurst, Tamma, and Maples answered live and tweeted questions addressing current issues in antimicrobial stewardship. Networking and fun continued through the evening as Washington University hosted a dinner at the Westin hotel (and several groups migrated thereafter to watch NBA finals and/or the Spelling Bee Championship.)

The second day of the conference focused on national efforts in antimicrobial stewardship. Barbara Warner, MD, Washington University/St. Louis Children’s Hospital, discussed the relationship between the neonatal microbiome and neonatal enterocolitis and the difficult balance between promoting “good” organisms while preventing “bad” organisms. Jeffrey Linder, MD, MPH, Northwestern, presented developments in outpatient antimicrobial prescribing and behavioral approaches, including a brief overview of the BEARI trial (“You are a top performer” vs. “You are not a top performer”). Katherine Fleming-Dutra, MD, returned with an update on the CDC’s continuing national antimicrobial stewardship efforts. She demonstrated the CDC’s interactive map of antimicrobial prescribing and the rate of acute care hospitals meeting the proposed core elements. She also informed the audience that “Get Smart about Antibiotics Weeks” is going to undergo some rebranding (to “Antibiotic Awareness Week”) and asked us to join in on the efforts November 13-19. David Hyun, MD, in a return performance,  presented on the changing legislative and policy landscape affecting antimicrobial stewardship, highlighting potential effects of altering the Affordable Healthcare Act as well as Centers for Medicaid and Medicare Services proposed hospital requirements for antimicrobial stewardship that appear to be on hold.

Several abstracts are submitted for poster presentation and a few are selected for oral presentation in the afternoon. This year, abstracts were presented by:

  • Heidi Andersen, MD, MS, Cincinnati Children’s Hospital Medical Center “Precision metagenomics detects colonization, invasion and transmission of multidrug-resistant bacteria”
  • Kevin Messacar, MD, Children’s Hospital Colorado “Development of an integrated diagnostic and antimicrobial stewardship approach to rapid diagnostic testing in children with suspected central nervous system infections”
  • Katherine Cook, PharmD, Monroe Carell Jr. Children’s Hospital at Vanderbilt, “Incidence of Nephrotoxicity among pediatric patients receiving vancomycin with either piperacillin/tazobactam or cefepime”
  • Jason Child, PharmD, Children’s Hospital Colorado, “Pharmacokinetic and pharmacodynamics properties of metronidazole in pediatric patients with acute appendicitis”
  • Kathryn Timberlake, PharmD,The Hospital for Sick Children, “Reducing vancomycin in the neonatal intensive care unit” 

Jason Newland, MD, MEd rounded out the meeting with an update of the Sharing Antimicrobial Reports for Pediatric Stewardship (SHARPS) collaborative. The collaborative initially started with handful of children’s hospitals throughout the US and now has grown to include 45 pediatric institutions! Participants in the SHARPS collaborative attend a monthly webinar presented by other members of the group and meet annually prior to the pediatric antimicrobial stewardship meeting.

After eight years and a change in location (bye, Kansas City – hello, St. Louis!), the International Pediatric Antimicrobial Stewardship Conference continues to grow and expand. Additionally, with an increasing legislative and regulatory support for antimicrobial stewardship, it continues to be a wonderful resource for both new and experienced practitioners.

Written By: 

Rana Hamdy, MD, MPH, Children's National Health System
Diana Yu, PharmD, Doernbecher Children's Hospital

In the recent issue of the Journal of the Pediatric Infectious Diseases Society, Paydar-Darian et al examine the role of lumbar puncture (LP) on management of children with facial palsy in a Lyme endemic area (1). The authors performed a retrospective cross sectional study of 620 children with peripheral facial palsy who presented to a single emergency department in a Lyme disease endemic area. Case of Lyme associated facial palsy was defined as the presence of clinically diagnosed erythema migrans or positive 2 tier serology test. The primary outcome was whether an LP was performed. Of 620 unique patients, 211 had facial palsy due to Lyme disease. Other causes of facial palsy included mastoiditis, otitis media, trauma and presumptive herpes simplex infection. Clinicians were more likely to perform LP on patients presenting with headache, meningitis and during summer months. The median cerebrospinal fluid (CSF) count was higher among patients with Lyme disease compared to other patients, 61 cells/mm3 (IQR 18-155) vs 2 cells/mm3 (IQR 1-3 cells/mm3). Majority, 70 (86%) of patients with Lyme disease had CSF pleocytosis. Children who underwent LP were more likely to have received parenteral antibiotics 71/149 (63%) LP performed vs 6/80 (2%) no LP performed and were more likely to be hospitalized 87/140 ( 62%) LP performed vs 29/480 (6%) LP not performed. The authors conclude that LP maybe useful in patients with unknown cause of meningitis but question its utility for patients with confirmed Lyme infection (1).

This study addresses an important clinical dilemma regarding a need for LP in patients with facial palsy due to suspected Lyme disease. LP is recommended for patients with facial palsy and symptoms consistent meningitis. For patients with CSF pleocytosis, the AAP Committee on Infectious Diseases Red Book committee recommends ceftriaxone or cefotaxime. Oral doxycycline is recommended for patients with severe allergy to cephalosporins as an alternative to cephalosporin desensitization (2). Multiple European studies showed that oral doxycyline is an acceptable alternative to parenteral antibiotics for treatment of neuroboreliosis. Oral doxycycline is inexpensive, rapidly absorbed and its bioavailability (when taken on empty stomach) is excellent (>90%), (3). CNS penetration exceeds the estimated MIC for B burgdorferi (4). Given the morbidity associated with the use of peripherally inserted central catheters (5) and unclear benefit of parenteral antibiotics over oral doxycycline, their use is increasingly questioned (1, 6). Oral doxycycline has been shown to be effective in treating facial palsy and meningitis due to Lyme disease in European pediatric and adult populations but data from the US are lacking. Lyme neuroboreliosis in Europe is primarily caused by B garinii and or B afzelii. It is not clear whether this experience can be extrapolated to the US population where neuroboreliosis is caused by B burgdorferii sensu stricto. The clinical efficacy of oral doxycycline in US Lyme neuroborreliosis should be further examined.

So which patients need LP?  Patients who present with meningitis and facial palsy due to unknown cause or who are ill appearing should undergo a diagnostic LP in order to determine etiology and best treatment. Advent of CSF multiplex PCR panels aid in rapid diagnosis of common causes of meningitis and further increase the utility of LP. Patients with facial palsy without meningitis can be safely treated with oral antibiotics. Because patients with Lyme facial palsy often have CSF pleocytosis even in the absence of symptoms of meningitis, and can be safely treated with oral doxycycline, it is unclear what if any benefit LP adds to management of patients with known Lyme neuroborreliosis. Prospective comparative studies conducted in the US focusing on neuroborreliosis in older pediatric patients with CSF pleocytosis would assist clinicians in evidence based decisions regarding the safety and efficacy of oral doxycycline and the need for LP.

Written by: Jana Shaw, MD, MPH, SUNY Upstate Medical University


  1. Paydar-Darian N, Kimia AA, Lantos PM et al. Diagnostic Lumbar Puncture Among Children With Facial Palsy in a Lyme Disease Endemic Area. J Pediatric Infect Dis Soc. 2017; 6: 205-208.
  2. Lyme disease. In: Kimberlin DW, Jackson MA, Long SS, ed. Red Book: 2015 Report of the Committee on Infectious Diseases. 30 ed. Elk Grove Village, IL. American Academy of Pediatrics 2015:516-523.
  3. Saivin SHouin G. Clinical pharmacokinetics of doxycycline and minocycline. Clin Pharmacokinet. 1988 Dec;15(6):355-66.
  4. Dotevall L, Hagberg L. Successful oral doxycycline treatment of Lyme disease-associated facial palsy and meningitis. Clin Infect Dis 1999; 28: 569–74.
  5. Thompson ADCohn KAShah SS et al. Treatment complications in children with Lyme meningitis. Pediatr Infect Dis J. 2012; 31:1032-5.
  6. Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1089–134.
  7. Dotevall L, Hargberg L. Penetration of Doxycycline into Cerebrospinal Fluid in Patients Treated for Suspected Lyme Neuroborreliosis . Antimicrob Agents Chemoth.1989; 33: 1078-1080

Following the introduction of routine childhood vaccination against rotavirus, a common cause of diarrheal illness, more than 380,000 children avoided hospitalization for diarrhea from 2008 to 2013 in the U.S., thus saving an estimated $1.2 billion in direct medical costs. The estimates, from a new study published in the Journal of the Pediatric Infectious Diseases Society, provide additional evidence for the substantial impact of routine rotavirus vaccination. They also suggest even greater benefits from immunization if other avoided costs were to be considered.

For the study, researchers analyzed data from community and academic hospitals in 26 states, focusing on hospitalizations for acute gastroenteritis among children under 5 years old, to estimate the impact of rotavirus vaccination nationwide. They compared periods before and after vaccination licensure in 2006, excluding the first year during which vaccine coverage rates were low and uneven. Following the start of routine rotavirus vaccination in 2006, diarrhea hospitalizations decreased by between 31 percent to 55 percent from 2008 to 2013, with greater reductions in the later years. The researchers estimated that more than 380,000 hospitalizations for severe diarrhea in children younger than 5 were avoided across the U.S. during this six-year period.

“Our findings confirm the sustained impact and effectiveness of the rotavirus vaccine program,” said author Eyal Leshem, MD, formerly of the Centers for Disease Control and Prevention (CDC) at the time of the study and who is currently affiliated with the Sackler Faculty of Medicine at Tel-Aviv University in Israel. “Increasing vaccine coverage likely resulted in the larger declines of rotavirus hospitalizations observed in the later years studied.”

The researchers estimated that the direct medical cost savings from avoided hospitalizations for diarrhea in infants and young children were $1.2 billion nationwide during the 2008-2013 period. This amount likely underestimates the overall economic impact, the study authors noted, because other costs, such as those associated with averted doctor’s office or emergency room visits for rotavirus disease, were not included in their analysis.

In 2015, an estimated 73 percent of U.S. children 19-35 months old received rotavirus vaccines, lower than rates for other routine childhood vaccines, including the diphtheria, tetanus, and acellular pertussis (DTaP) vaccine, which 95 percent of the children in this same age group received, according to CDC. Future research should explore the reasons behind the lower than optimal rotavirus immunization rates and interventions to improve them, Dr. Leshem said. “Efforts to further increase rotavirus vaccine coverage rates to better protect all children in the U.S. against rotavirus disease should continue.”

Fast Facts

  • Rotavirus is a common cause of diarrheal illness in infants and young children in the United States.
  • Diarrhea hospitalizations in U.S. children under 5 decreased by between 31 percent and 55 percent from 2008 to 2013, following the start of routine rotavirus vaccination in 2006.
  • Researchers estimated that more than 380,000 diarrhea hospitalizations were averted nationwide during this six-year period, saving an estimated $1.2 billion in direct medical costs.

Click here to read the study published in the Journal of the Pediatric Infectious Diseases Society. 


Published quarterly, the Journal of the Pediatric Infectious Diseases Society represents the spectrum of peer-reviewed, scientific and clinical information on perinatal, childhood, and adolescent infectious diseases. The journal is a publication of the Pediatric Infectious Diseases Society (PIDS), the world's largest professional organization of experts in the care and prevention of infectious diseases in children.

PIDS membership encompasses leaders across the global scientific and public health spectrum, including clinical care, advocacy, academics, government, and the pharmaceutical industry. From fellowship training to continuing medical education, research, regulatory issues and guideline development, PIDS members are the core professionals advocating for the improved health of children with infectious diseases both nationally and around the world, participating in critical public health and medical professional advisory committees that determine the treatment and prevention of infectious diseases, immunization practices in children, and the education of pediatricians. For more information, visit

Remarks of HIVMA Board Chair Wendy Armstrong, MD, FIDSA:

As the U.S. Senate considers action on the “Better Care Reconciliation Act of 2017,” the HIV Medicine Association, Infectious Diseases Society of America and the Pediatric Infectious Diseases Society are releasing a position paper on the Medicaid Program and the pivotal role the program plays in public health and providing access to necessary services and treatment for people living with HIV. The Policy Statement on the Medicaid Program, Public Health and Access to HIV Care is here.

The policy positions articulated in the paper reflect the individual and public health imperatives of uninterrupted access to medical services and to antiretroviral treatment for people living with HIV, and the benefits that have been realized since the Medicaid expansion under the Affordable Care Act.

The Medicaid program and more recently the Medicaid expansion have been pivotal to progress against the HIV epidemic in the U.S. because consistent access to care and treatment for people with HIV allows them to stay healthy, have a near normal life expectancies and prevents transmission of the virus. The program is important to preventing the transmission of HIV by pregnant women to their babies by providing access to care and treatment for low-income mothers and their newborns. Covering more than 40 percent of patients with HIV, the Medicaid program plays an essential role in improving the lives of people with HIV and in preventing new HIV infections.

At a time when the U.S. House of Representatives has approved deep cuts to Medicaid spending through a per person cap on federal funding and an end to the Medicaid expansion, when the Senate is close to taking similar actions without stakeholder input, the program’s importance to people with HIV, and to control the epidemic must be weighed. HIVMA, IDSA and PIDS recommend policies that:

  • Maintain the Medicaid Program as a program supported by an open-ended federal/state matching formula giving states flexibility to respond to disease outbreaks, increases in healthcare costs and to medical advances, including those seen in recent years in treatments for HIV, cancer, and hepatitis C;
  • Continue the Medicaid expansion with federal financing that will remain fixed at 90 percent of costs in 2020;
  • Ensure that Medicaid beneficiaries have access to the range of services they need to stay healthy by maintaining the current minimum benefits and coverage requirements and by expanding requirements to ensure all Medicaid beneficiaries have access to critical services, including preventive screenings, prescription drugs, mental health and substance use treatment;
  • Maintain protections that limit premiums and cost sharing based on income and continue to bar denial of medical care for failure to pay cost sharing for those enrollees with incomes under 100% of the federal poverty level;
  • Ensure access to adequate services so Medicaid beneficiaries can stay healthy and able to work, care for their families, and/or pursue educational and training opportunities without linking Medicaid eligibility to work requirements;
  • Continue support for waivers that allow states to evaluate innovative delivery systems as well as benefit and payment models that promote high quality, comprehensive, cost effective care;
  • And evaluate models for improving Medicaid provider payment equity.


HIVMA is an organization of nearly 5,000 clinicians and researchers whose professional focus is HIV medicine. HIVMA’s mission is to promote quality in HIV care by advocating policies and supporting programs that ensure a comprehensive and humane response to the AIDS pandemic informed by science and social justice. Nested within the Infectious Diseases Society of America, HIVMA's work includes creating clinical and educational tools and resources; supporting clinical training and research opportunities to build HIV workforce capacity; and promoting policies and programs to improve access to HIV prevention and care.

About IDSA

The Infectious Diseases Society of America (IDSA) represents physicians, scientists and other health care professionals who specialize in infectious diseases. IDSA’s purpose is to improve the health of individuals, communities, and society by promoting excellence in patient care, education, research, public health, and prevention relating to infectious diseases.

About PIDS

PIDS is the world's largest organization of professionals dedicated to the treatment, control and eradication of infectious diseases affecting children. Membership is comprised of physicians, doctoral- level scientists and others who have trained or are in training in infectious diseases or its related disciplines, and who are identified with the discipline of pediatric infectious diseases or related disciplines through clinical practice, research, teaching and/or administration activities.

Pillars - PIDSThe PIDS 2017 Spring Business Meeting was held on Monday, May 8, in conjunction with the PAS Meeting, in San Francisco, California.  Dr. Janet Gilsdorf, PIDS President, gave her farewell report on the state of the Society.  She reminded members of PIDS’ vision and mission statements along with the 2015-2017 strategic pillars that derived from the 2015 strategic planning meeting.

Dr. Gilsdorf then provided a brief summary of activities for a few of the pillars.  She also thanked the PIDS Board of Directors, committee chairs, and liaisons for working so diligently to accomplish the Society’s mission. 

Next, Dr. Gilsdorf provided membership statistics for the last seven years noting the increase in the number of resident and medical student memberships in 2016-2017.  She then reminded members to pay their 2017 member dues if they had not already done so and introduced Dr. Charles Woods, Secretary-Treasurer, to update members on the financial status of PIDS.

PIDS End of Year Net Worth chartDr. Woods provided a list of all sources of revenue and the major expenses of the Society.  He then provided a comprehensive report of the operational and foundation accounts, concluding that PIDS’ 2016 “End of the Year Net Worth” is $2,934,927.

Dr. Gilsdorf then announced the 5th year anniversary of the Journal of the Pediatric Infectious Diseases Society (JPIDS), provided a brief snapshot of the journal’s accomplishments over the last 5 years, and thanked Dr. Theo Zaoutis, JPIDS Editor-in-Chief, for his leadership and the associate editors for their diligence in making the journal successful.

JPIDS Celebrates 5 yearsDr. Zaoutis expressed sincere gratitude to the Society for allowing him to serve as editor and noted that continued success relies heavily on manuscript submissions from PIDS members.  He then encouraged members to submit their original science to JPIDS.

Dr. Gilsdorf then announced the 2017 PIDS election results. 

  • Officers:  Dr. Kris Bryant, President-Elect and Dr. Buddy Creech, Secretary-Treasurer
  • Board of Directors Members-at-Large:  Dr. Jason Newland and Dr. Debra Palazzi
  • Nominations and Awards Committee:  Dr. Angela Campbell, Dr. Lara Danziger-Isakov, and Dr. John Williams

Congratulations to all!

2017-2019 AimsDr. Gilsdorf also thanked Drs. David Kimberlin and Buddy Creech for their service on the PIDS Board and thanked the Society for allowing her to serve as President for the past two years.  With that said, she announced Dr. Paul Spearman as the incoming PIDS President.  Dr. Spearman provided the PIDS Aims discussed at this year’s strategic planning meeting.  These Aims will govern the Society’s activities for the next two years.

A summary of the strategic planning meeting will be provided in the June issue of PIDSNews.  The business meeting concluded at 5:50 pm PDT. Click here to view the full business meeting slide presentation.

Vision Statement: Freedom from infections for all children through excellent clinical care, research, education and advocacy.

Mission Statement: To enhance the health of infants, children, and adolescents by promoting excellence in diagnosis, management and prevention of infectious diseases through clinical care, education, research and advocacy.

It has been my great honor to serve as PIDS President for the past two years and have been amazed at the generosity of our members in giving their time and expertise to PIDS’ many activities.


PIDS leadership and staff have made great strides in developing and implementing projects directed at the seven focus areas that came out of the 2015 PIDS strategic planning session.  While some projects are still ongoing, PIDS has accomplished the following:

Pillar 1: Value of PID to the Healthcare System

  • Established Value of Pediatric Infectious Diseases Workgroup
    • The workgroup drafted a manuscript based on the results of the Value qualitative study.  The manuscript is currently under review.
    • The quantitative study to evaluate the impact of PID consultation on patient outcomes is currently in the data analysis phase.
    • The committee plans to author a white paper, based on these study results, to emphasize the value of PID.
    • The Value workgroup is also working to develop deliverables for disseminating to PIDS members.
  • Developed an opinion piece on what’s next for AS in pediatrics as well as a toolkit for small pediatric and community hospitals through input from the Pediatric Committee on Antibiotic Stewardship (PCAS).  Both projects are expected to be completed by the end of the year.
  • Established collaborative initiatives with AAP, IDSA, SHEA, and other organizations on AR and ASP.  Some initiatives include:
    • Developed  a white paper on ID Physician Leadership on ASP (in progress)
    • Collaborated with IDSA’s Multistakeholder Measure Development Workgroup to establish stewardship measures to report to CMS
    • Collaborated with Stakeholder Forum on Antimicrobial Resistance (S-FAR) Group (ongoing)
    • Established the AAP/PIDS Antimicrobial Resistance and Stewardship Workgroup to assess current practices that impact antimicrobial stewardship within pediatrics and develop educational programming for NCE (in progress)
    • Established the IDSA/SHEA/PIDS Stewardship Leadership Group to identify new collaborative initiatives as well as minimize overlap in activities with some of the same external organizations on various issues/at different times (ongoing)

Pillar 2: Recruitment of Future ID Pediatricians

  • Developed recruitment tools for utilization by pediatric infectious disease programs.  Efforts include:
    • Fellow Video Contest on “A Day in the Life of an ID Fellow”
    • Several videos of PIDS members telling their stories
      • What is a “Day in the Life of a Peds ID Doc?
      • How did you decide on this career path?
      • What parts of your career give you the great satisfaction?
      • How do you balance your professional and personal life?
      • How did Peds ID assist in advancing you to your current position?
      • What would you say to someone to encourage them to become a Pediatric ID specialist?
    • Message from the President – Membership Video
    • Updated career brochure
  • Worked with IDSA to enhance interest in ID as a specialty
  • Submitted NIH R13 Conference Grant for residents & students to attend St. Jude/PIDS conferences (funded) 

Pillar 3: Training & Guidance for PID Fellows

  • Developed Fellows’ Survival Guide, with templates for inquiring about job opportunities
  • Improved Fellows’ Day at IDWeek
  • Established very popular Fellows Networking Happy Hour at IDWeek 
  • Appointed fellows to committees/assigned projects
  • Developed  online educational modules (in progress)
  • Established Career Development sessions at St. Jude/PIDS conferences
  • ASP Basics Workshop at the ASP Conference

Pillar 4: Research activities related to PID

  • Increased fellowship/research award opportunities
  • Developed research opportunities for PIDS Transplant Network (in progress)
  • Implemented a clinical observership exchange program with ANZPID

Pillar 5: Engagement of new and established PIDS members

  • Increased visibility at meetings
  • Identified new member prospects (ongoing)
  • Created a digital archive and release it via Twitter, Facebook and the PIDS website 
  • Increased member involvement in committee activities
  • Increased international members

Pillar 6: Growth of the Pediatric Infectious Diseases Society Education and Research Foundation

  • Established the Resource Development Committee to assist staff in identifying potential funding opportunities (ongoing)
  • Expanded opportunities for philanthropic giving to the Foundation
  • Created the foundation website 
    • Who we are? 
    • Fellowship Infographics report to summarize the successful outcome of the Fellowship Awards Program and past fellowship award recipients 
    • Education and Research Programs
    • How to contribute with donation link

Pillar 7: Success of the Journal of Pediatric Infectious Diseases Society

  • Celebrated JPIDS’ fifth birthday 
  • Increased revenue
  • Increased visibility at meetings
  • Maintained manuscript submissions
  • Identified potential collaborations with international societies (ongoing)
  • Enhanced options for on-line only publication

It’s been a very productive two years.  We all look forward to the extremely capable leadership of our next President, Dr. Paul Spearman, in moving our Society into an even brighter tomorrow.


Attending conferences and symposia as pediatric infectious diseases fellows is usually an exciting and intellectually stimulating experience. Seeing advances in research presented, learning about varying topics from around the world, and meeting leaders in the field make any large gathering of infectious diseases physicians a great learning opportunity.

As a 3rd year fellow, after having the privilege of attending more than 10 conferences as a trainee at this point, I looked forward to the PIDS Transplant Symposium and Research Conference this year just a little more than all of the others. It has the added benefit above all others I’ve attended of being smaller, more manageable in size and schedule, and being specifically focused on the needs of fellows and early career infectious diseases physicians.

After learning from the presenters at the conference, I was then able to come back and share with my section at Tulane in New Orleans the numerous topics I had learned in my time in Memphis. I was able to discuss with them Dr. Ann Leen’s research on infusions of activated T-cells for preventing transplant-associated viral infections, present Dr. David O’Connor’s findings on Zika virus infection in a Rhesus Macaque model, and review Dr. Miriam Laufer’s research on malaria. Over the course of 1 of hour-long weekly section conferences, we also briefly discussed neonatal tolerance in solid organ transplantation, how the microbiome can affect bone marrow transplant patients, and the lack of effect of treatment of schistosomiasis in pregnant women.

The PIDS Transplant Symposium and Research Conference in Memphis has been a wonderful learning opportunity for me as a trainee, and my entire section has been very interested in learning from the topics presented each year, even if they are not in attendance. This wonderful learning opportunity from PIDS and St. Jude has benefited our entire group of Pediatric Infectious Diseases specialists at Tulane in New Orleans, and I know I will continue to look forward to attending and learning in the future!